Xintela AB (publ) (XINT.ST)
- Previous Close
0.2600 - Open
0.2600 - Bid 0.2540 x --
- Ask 0.2650 x --
- Day's Range
0.2540 - 0.2800 - 52 Week Range
0.2100 - 0.3490 - Volume
192,781 - Avg. Volume
264,129 - Market Cap (intraday)
148.556M - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
www.xintela.seRecent News: XINT.ST
Performance Overview: XINT.ST
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XINT.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XINT.ST
Valuation Measures
Market Cap
147.42M
Enterprise Value
137.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
358.05
Price/Book (mrq)
--
Enterprise Value/Revenue
363.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-166.73%
Return on Equity (ttm)
-1,064.94%
Revenue (ttm)
78k
Net Income Avi to Common (ttm)
-54.08M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.81M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-35.62M